Institutional investors purchased a net $172.6 thousand shares of RGEN during the quarter ended March 2017 and now own 88.57% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CONESTOGA CAPITAL ADVISORS LLC Bought 76.0 Thousand shares of Repligen Corp
APERIO GROUP LLC Bought 19.7 Thousand shares of Repligen Corp